The effect of triplelizumab combined with TACE on the treatment of massive liver cancer and the levels of Wnt1, β-catenin and DKK1

Abstract

Abstract: Objective To investigate the effect of triplimab combined with hepatic arterial chemoembolization (TACE) on the treatment of massive liver cancer and the levels of Wnt1 protein (Wnt1), β-catenin and secreted protein Dickkopf1 (DKK1). Methods Seventy-six cases of massive liver cancer treated from May 2020 to October 2022 were selected and divided into an observation group and a control group according to random number table method with 38 cases in each group.The control group was treated with TACE, and the observation group was treated with 240mg of terriplizumab at 1 week after TACE, followed by once every 3 weeks. The efficacy was evaluated in 6 weeks after operation. Alpha-fetoprotein (AFP), vascular endothelial growth factor (VEGF), Wnt1, β-catenin and DKK1 were detected before treatment and 6 weeks after treatment. The change of quality of life was evaluated by KPS. The incidence of adverse reactions and progression-free survival time (PFS) during treatment were analyzed. Results The objective remission rate (ORR) of the observation group was higher than that of the control group (P<0.05). After 6 weeks of treatment, the levels of AFP, VEGF, β-catenin and DKK1 in both groups decreased, whereas the levels of Wnt1 increased, and the change range of the observation group was greater than that of the control group (P<0.05). The improvement of life quality in the observation group was higher than that in control group (P<0.05). There was no significant difference in the incidence of adverse reactions between these two groups (P>0.05).The PFS of the observation group was 6 (2,8) months, which was longer than that of 3 (1,5) months in the control group(P<0.05). Conclusion Triprilizumab combined with TACE has definite efficacy in the treatment of massive liver cancer, and it can regulate AFP and VEGF levels, inhibit Wnt signaling pathway, promote the patients’ quality of life, prolong the survival of patients, with controllable safety.

Key words: Triprimab, Hepatic arterial chemoembolization, Massive liver cancer, Wnt1 protein, β-connexin, Secretory protein Dickkopf1

ZHANG Yue-xin, ZHENG Wen-hong, WU De-jian, TAN Yi-xuan, ZHOU Cong. The effect of triplelizumab combined with TACE on the treatment of massive liver cancer and the levels of Wnt1, β-catenin and DKK1[J]. Chinese Hepatolgy, 2024, 29(11): 1352-1357.

References

[1] Sun M, Shang P, Bai J, et al. High-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization improves long-term efficacy and prognosis of primary liver cancer[J]. J Clin Lab Anal,2021,35(2):e23633.
[2] 吴水天.CT增强扫描在评估原发性肝细胞肝癌TACE术后疗效中的应用[J].中国CT和MRI杂志,2022,20(3):91-93.
[3] 段彬,罗成静,罗海阳.Callispheres可载药栓塞微球联合多西紫杉醇TACE对原发性肝癌患者bFGF VEGF和MVD的影响[J].河北医学,2019,25(1):14-18.
[4] 冯超凡,胡继红,张学贤,等.DEB-TACE联合MWA及阿帕替尼治疗巨块型肝癌的临床疗效[J].介入放射学杂志,2022,31(3):254-258.
[5] 冉方兰,张孝彬,卢安静,等.特瑞普利单抗注射液联合长春瑞滨+顺铂化疗一线治疗晚期NSCLC的效果及对外周血淋巴细胞PD-1变化的影响.实用药物与临床,2022,25(11):981-985.
[6] 晏如,郭胜杰,安欣,等.特瑞普利单抗和尼妥珠单抗联合化疗用于不可切除Ⅳ期阴茎鳞状细胞癌新辅助治疗的效果及安全性[J].中华外科杂志,2022,60(12):1093-1099.
[7] 周莉,许华艳,鄢谢桥,等.特瑞普利单抗联合阿昔替尼在晚期肾癌中的初步应用[J].中华医学杂志,2022,102(2):136-140.
[8] 宋丽丽,陆赛花.特瑞普利单抗注射液联合XP方案治疗胃癌晚期的临床研究[J].中国中西医结合消化杂志,2022,30(2):128-132.
[9] 胡鹏蕴,赵宏峰,杨小伟,等.新型促癌基因LSM11通过Wnt/β-catenin信号通路促进肝癌细胞增殖[J].实用肝脏病杂志,2022,25(5):628-632.
[10] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].临床肝胆病杂志,2020,36(2):277-292.
[11] Ponzetti A, Laface R, Milanesi E, et al. Three proposals to optimise the Eastern Cooperative Oncology Group and Karnofsky Scales in the molecular and COVID-19 Era[J]. Clin Oncol (R Coll Radiol),2021,33(3):e192.
[12] 张萍,艾斌.实体瘤免疫治疗疗效评价标准[J].国际肿瘤学杂志,2016,43(11):848-851.
[13] Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1[J].2020. J Natl Compr Canc Netw,2020,18(3):230-241.
[14] 中国医师协会介入医师分会.中国肝细胞癌经动脉化疗栓塞治疗临床实践指南[J].中华放射学杂志,2019,53(4):246-255.
[15] Wei ZQ, Zhang YW. Transcatheter arterial chemoembolization followed by surgical resection for hepatocellular carcinoma: a focus on its controversies and screening of patients most likely to benefit[J]. Chin Med J (Engl),2021,134(19):2275-2286.
[16] Finkelmeier F, Waidmann O, Trojan J. Nivolumab for the treatment of hepatocellular carcinoma[J]. Expert Rev Anticancer Ther,2018,18(12):1169-1175.
[17] Rizell M, Aberg F, Perman M, et al. Checkpoint inhibition causing complete remission of metastatic combined hepatocellular-cholangiocarcinoma after hepatic resection[J]. Case Rep Oncol,2020,13(1):478-484.
[18] 郑丽云,方世记,吴发宗,等.程序性死亡受体1抑制剂联合经导管动脉化疗栓塞术治疗巨块型肝癌的疗效及安全性研究[J].中华放射学杂志,2021,55(4):420-424.
[19] 何亚琳,杨嘉欣,程志强.SOX方案联合特瑞普利单抗治疗中晚期混合型肝细胞胆管细胞癌1例[J].中国医药导报,2022,19(9):181-184.
[20] 彭国文,史德刚,王健鹏,等.TACE联合索拉非尼及特瑞普利治疗中晚期原发性肝癌的效果[J].长治医学院学报,2022,36(5):339-343.
[21] Wang Z, Ying J, Xu J, et al. Safety, antitumor activity, and pharmacokinetics of toripalimab, a programmed cell death 1 inhibitor, in patients with advanced non-small cell lung cancer: a phase 1 trial[J]. JAMA Netw Open,2020,3(10):e2013770.
[22] Xing W, Zhao L, Zheng Y, et al. The sequence of chemotherapy and toripalimab might Influence the efficacy of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell cancer-a phase Ⅱ study[J]. Front Immunol,2021,12(1):772450.
[23] Liu S, Wang M, Zheng C, et al. Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer[J]. Clin Biochem,2020,79(1):54-60.
[24] 孙恒亮, 濮忠建.血清甲胎蛋白和三叶因子1水平对原发性肝癌的诊断及预后价值[J].中国肝脏病杂志(电子版),2021,13(4):27-37.
[25] Guo S, Li J, Huang Z, et al. The CBS-H2S axis promotes liver metastasis of colon cancer by upregulating VEGF through AP-1 activation[J]. Br J Cancer,2022,126(7):1055-1066.
[26] 沈皓,陈瑶,夏勇,等.血清VEGF与肝癌肝切除术后肝功能衰竭风险的巢式病例对照研究[J].肝胆外科杂志,2021,29(1):20-24.
[27] 吴君,韩萍,张志勇,等.血清VEGF、AFP水平对晚期肝癌TACE联合PD-1抑制剂疗效的评估价值[J].山东医药,2022,62(19):16-19.
[28] 魏涛.奥沙利铂介入治疗原发性肝癌的疗效及对患者血清CXCL9、HSP90水平的影响[J].实用癌症杂志,2021,36(5):814-819.
[29] Kaur H. Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development[J]. Crit Rev Biotechnol, 2021, 41(2):300-315.